These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 32058812)
1. The Search for Biomarkers of Alzheimer's Disease in Down Syndrome. Handen BL Am J Intellect Dev Disabil; 2020 Mar; 125(2):97-99. PubMed ID: 32058812 [TBL] [Abstract][Full Text] [Related]
2. Down Syndrome, Partial Trisomy 21, and Absence of Alzheimer's Disease: The Role of APP. Doran E; Keator D; Head E; Phelan MJ; Kim R; Totoiu M; Barrio JR; Small GW; Potkin SG; Lott IT J Alzheimers Dis; 2017; 56(2):459-470. PubMed ID: 27983553 [TBL] [Abstract][Full Text] [Related]
3. Blood-based biomarkers for Down syndrome and Alzheimer's disease: A systematic review. Petersen ME; O'Bryant SE Dev Neurobiol; 2019 Jul; 79(7):699-710. PubMed ID: 31389185 [TBL] [Abstract][Full Text] [Related]
4. [Elucidating Pathogenic Mechanisms of Early-onset Alzheimer's Disease in Down Syndrome Patients]. Asai M; Kawakubo T; Mori R; Iwata N Yakugaku Zasshi; 2017; 137(7):801-805. PubMed ID: 28674290 [TBL] [Abstract][Full Text] [Related]
5. Targeting increased levels of APP in Down syndrome: Posiphen-mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model. Chen XQ; Salehi A; Pearn ML; Overk C; Nguyen PD; Kleschevnikov AM; Maccecchini M; Mobley WC Alzheimers Dement; 2021 Feb; 17(2):271-292. PubMed ID: 32975365 [TBL] [Abstract][Full Text] [Related]
6. Down syndrome and Alzheimer's disease: Common pathways, common goals. Hartley D; Blumenthal T; Carrillo M; DiPaolo G; Esralew L; Gardiner K; Granholm AC; Iqbal K; Krams M; Lemere C; Lott I; Mobley W; Ness S; Nixon R; Potter H; Reeves R; Sabbagh M; Silverman W; Tycko B; Whitten M; Wisniewski T Alzheimers Dement; 2015 Jun; 11(6):700-9. PubMed ID: 25510383 [TBL] [Abstract][Full Text] [Related]
7. Association between genetic variants in sortilin-related receptor 1 (SORL1) and Alzheimer's disease in adults with Down syndrome. Lee JH; Chulikavit M; Pang D; Zigman WB; Silverman W; Schupf N Neurosci Lett; 2007 Sep; 425(2):105-9. PubMed ID: 17826910 [TBL] [Abstract][Full Text] [Related]
8. Plasma metabolites related to cellular energy metabolism are altered in adults with Down syndrome and Alzheimer's disease. Gross TJ; Doran E; Cheema AK; Head E; Lott IT; Mapstone M Dev Neurobiol; 2019 Jul; 79(7):622-638. PubMed ID: 31419370 [TBL] [Abstract][Full Text] [Related]
9. Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. Fortea J; Vilaplana E; Carmona-Iragui M; Benejam B; Videla L; Barroeta I; Fernández S; Altuna M; Pegueroles J; Montal V; Valldeneu S; Giménez S; González-Ortiz S; Muñoz L; Estellés T; Illán-Gala I; Belbin O; Camacho V; Wilson LR; Annus T; Osorio RS; Videla S; Lehmann S; Holland AJ; Alcolea D; Clarimón J; Zaman SH; Blesa R; Lleó A Lancet; 2020 Jun; 395(10242):1988-1997. PubMed ID: 32593336 [TBL] [Abstract][Full Text] [Related]
14. Down syndrome and Alzheimer's disease: common molecular traits beyond the amyloid precursor protein. Gomez W; Morales R; Maracaja-Coutinho V; Parra V; Nassif M Aging (Albany NY); 2020 Jan; 12(1):1011-1033. PubMed ID: 31918411 [TBL] [Abstract][Full Text] [Related]
15. Down syndrome and Alzheimer's disease: a link between development and aging. Lott IT; Head E Ment Retard Dev Disabil Res Rev; 2001; 7(3):172-8. PubMed ID: 11553933 [TBL] [Abstract][Full Text] [Related]
16. Transfer of the amyloid β and/or of β-amyloid precursor protein of the fetus with trisomy 21 to the maternal blood stream and its possible contribution to the pathogenesis of the maternal Alzheimer's Disease. Mohamad López H Med Hypotheses; 2011 Dec; 77(6):1058-61. PubMed ID: 21944886 [TBL] [Abstract][Full Text] [Related]
17. Lysosomal Dysfunction in Down Syndrome Is APP-Dependent and Mediated by APP-βCTF (C99). Jiang Y; Sato Y; Im E; Berg M; Bordi M; Darji S; Kumar A; Mohan PS; Bandyopadhyay U; Diaz A; Cuervo AM; Nixon RA J Neurosci; 2019 Jul; 39(27):5255-5268. PubMed ID: 31043483 [TBL] [Abstract][Full Text] [Related]
18. Integrating Biomarker Outcomes into Clinical Trials for Alzheimer's Disease in Down Syndrome. Rafii MS; Zaman S; Handen BL J Prev Alzheimers Dis; 2021; 8(1):48-51. PubMed ID: 33336224 [TBL] [Abstract][Full Text] [Related]
19. Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. Fortea J; Carmona-Iragui M; Benejam B; Fernández S; Videla L; Barroeta I; Alcolea D; Pegueroles J; Muñoz L; Belbin O; de Leon MJ; Maceski AM; Hirtz C; Clarimón J; Videla S; Delaby C; Lehmann S; Blesa R; Lleó A Lancet Neurol; 2018 Oct; 17(10):860-869. PubMed ID: 30172624 [TBL] [Abstract][Full Text] [Related]
20. Cognitive decline and dementia in Down syndrome. Hithersay R; Hamburg S; Knight B; Strydom A Curr Opin Psychiatry; 2017 Mar; 30(2):102-107. PubMed ID: 28009725 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]